Low-dose fluvastatin reverses the hypoxic pulmonary adventitial fibroblast phenotype in experimental pulmonary hypertension

Keyphrases

• Experimental Pulmonary Hypertension 100%
• Fibroblast Phenotype 100%
• Fluvastatin 100%
• Adventitial Fibroblasts 100%
• Statins 60%
• P38 Mitogen-activated Protein Kinase (p38 MAPK) 60%
• Hypoxic Pulmonary Hypertension 60%
• Fibroblast Proliferation 60%
• Pulmonary Artery 40%
• Rac1 40%
• Phenotypic Change 40%
• Mitogen 40%
• Public Health Risk 20%
• Fibroblasts 20%
• Conditioned Medium 20%
• Mechanism of Action 20%
• Lung Disease 20%
• Pulmonary Artery Smooth muscle Cells (PASMCs) 20%
• Bovine Cells 20%
• Pulmonary Artery Smooth muscle Cell Proliferation 20%
• Chronic Hypoxia 20%
• Pulmonary Vascular Remodeling 20%
• Signaling Pathway 20%
• Co-culture Model 20%
• P38 Mitogen-activated Protein Kinase Inhibitor 20%
• High-altitude Resident 20%
• Kinase Phosphorylation 20%
• Treprostinil 20%
• Cholesterol Pathway 20%
• Sildenafil 20%
• Bosentan 20%
• Phenotypic Switching 20%

Pharmacology, Toxicology and Pharmaceutical Science

• Experimental Pulmonary Hypertension 100%
• Fluindostatin 100%
• Pulmonary Hypertension 60%
• Mitogen Activated Protein Kinase P38 60%
• Hydroxymethylglutaryl Coenzyme A Reductase Inhibitor 40%
• Mitogenic Agent 40%
• Hypoxia 20%
• Vascular Remodeling 20%
• Lung Disease 20%
• Mitogen Activated Protein Kinase P38 Inhibitor 20%
• Sildenafil 20%
• Bosentan 20%
• Treprostinil 20%
• Statin (Protein) 20%
• Diseases 20%